MEDICAL COLLEGE OF WISCONSIN

Oncologists commonly target 2 years of immunotherapy treatment in advanced NSCLC before considering discontinuation, based on evidence showing many patients maintain durable responses after stopping treatment.

Nyxoah's DREAM pivotal study data published in the Journal of Clinical Sleep Medicine demonstrates 90% patient satisfaction with the Genio hypoglossal neurostimulation system for obstructive sleep apnea treatment.

Ryght AI raised $3 million in seed funding led by Foothill Ventures to advance its AI-powered clinical trial platform that creates digital twins of over 100,000 research sites worldwide.

The phase 3 ECOG-ACRIN EA4151 trial is investigating whether autologous hematopoietic cell transplantation (auto-HCT) still benefits mantle cell lymphoma patients in the era of improved first-line therapies.

A phase I/II study of adaptive manufactured lentiviral anti-CD20/anti-CD19 CAR T-cells demonstrated a 100% response rate with 88% complete responses in relapsed/refractory mantle cell lymphoma patients.

A qualitative study at a San Francisco safety-net hospital uncovered six interconnected themes characterizing Latine patients' experiences with psoriasis management and treatment decisions.

A phase III trial (EA4151) found that autologous stem cell transplantation (ASCT) did not improve overall survival in MCL patients with undetectable measurable residual disease (MRD) after initial treatment.

Zamto-cel, a tandem CD20/CD19 CAR T-cell therapy, demonstrated a 72.8% overall response rate and a 50.8% complete remission rate in r/r DLBCL patients.

• The PARSIFAL trial indicated no significant efficacy difference between palbociclib combined with fulvestrant versus letrozole, suggesting current practices of using CDK4/6 inhibitors with aromatase inhibitors remain valid. • Young-PEARL data supports using palbociclib plus an aromatase inhibitor and ovarian suppression over chemotherapy in premenopausal patients with ER-positive, HER2-negative metastatic breast cancer after tamoxifen progression. • Clinicians should carefully interpret adverse event data, as seen in Young-PEARL, where higher grade 3 adverse events in the palbociclib arm were mainly manageable asymptomatic neutropenia. • Ongoing research explores cemiplimab, a PD-1 inhibitor, in combination with standard chemotherapy for triple-negative and ER-positive/HER2-negative breast cancer, expanding eligibility to include PD-L2-positive patients.

Cilta-cel demonstrates significant survival benefits in multiple myeloma patients, even in late and early relapse scenarios.